CN115068494A - Application of icariin in preparation of medicine for treating irritable bowel syndrome - Google Patents
Application of icariin in preparation of medicine for treating irritable bowel syndrome Download PDFInfo
- Publication number
- CN115068494A CN115068494A CN202211005959.5A CN202211005959A CN115068494A CN 115068494 A CN115068494 A CN 115068494A CN 202211005959 A CN202211005959 A CN 202211005959A CN 115068494 A CN115068494 A CN 115068494A
- Authority
- CN
- China
- Prior art keywords
- group
- icariin
- bowel syndrome
- irritable bowel
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of icariin in preparation of a medicine for treating irritable bowel syndrome, belongs to the field of biological medicines, and finds that icariin has a prevention and treatment effect on the irritable bowel syndrome model by constructing the irritable bowel syndrome model and administering the icariin. Therefore, the icariin is used for preparing the irritable bowel syndrome medicament, can provide a natural medicament for treating the irritable bowel syndrome, develops a new application field, and provides a basis for the follow-up research of ICA for IBS.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to application of icariin in preparation of a medicine for treating irritable bowel syndrome.
Background
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal distension, abdominal pain and changes in Bowel habits, the pathogenesis of which has not been clearly elucidated so far. Many studies suggest that the cause of IBS is a result of the combined action of several factors, including abnormal gastrointestinal motility, abnormal visceral sensation, abnormal control of the brain and bowel, inflammation and psychology. IBS has no specific symptoms from the clinical picture, but the appearance or exacerbation of IBS symptoms is often associated with stress states or psychological factors, relative to organic gastrointestinal disease. Due to the above characteristics of the disease, development of an IBS model is difficult, and thus treatment costs of IBS patients are sharply increased. Because IBS symptoms often occur with psychological stress, conventional methods mostly construct IBS models by subjecting animals to various stress tests (e.g., chronic stimulation, tail-biting stimulation, etc.). Mainly comprises acute stress, chronic unpredictable stress models and the like. Among them, chronic unpredictable stress is widely used as a nonspecific and generalized reaction in model construction. Many studies have shown that visceral sensitivity is one of the most important physiological features that characterize IBS pathology, and thus numerous IBS models based on visceral hypersensitivity have emerged. The common visceral hypersensitivity model sensitizes animals mainly by physical and chemical stimuli.
The chronic stimulation molding method has long time, low molding efficiency and single characteristics of the chemical stimulation molding method. Based on the two model construction methods, the invention provides a rat model based on comprehensive stimulation IBS. On the basis of the psychological stress stimulation, the influence of the introduction of the chemical stimulation on an IBS model is further discussed, and a theoretical basis is provided for the preclinical research of IBS.
Icariin is a known compound of the formula C 33 H 40 O 15 . Icariin is known as a kidney-tonifying traditional Chinese medicine, and stimulates sensory nerves and indirectly stimulates libido by promoting semen secretion. The compound is known to have the effects of tonifying kidney and strengthening yang, resisting aging, inhibiting bacteria, resisting inflammation, reducing blood pressure and the like, but no report is available for treating irritable bowel syndrome.
Disclosure of Invention
In view of the above problems, the present invention aims at providing an application of icariin in the preparation of a medicament for treating irritable bowel syndrome, and aims at providing a medicament for treating irritable bowel syndrome. According to the invention, the icariin is administered in the modeling process by constructing the irritable bowel syndrome model, and the icariin with a certain concentration is found to be capable of effectively treating the irritable bowel syndrome.
In order to achieve the purpose, the invention adopts the following specific scheme:
the first aspect of the invention claims the use of icariin for the preparation of a medicament for the treatment of irritable bowel syndrome.
Preferably, the concentration of the icariin is 40-80 mg/kg. Further, the concentration of icariin was 60 mg/kg.
The second aspect of the invention requests to protect a medicine for treating irritable bowel syndrome, wherein the effective component of the medicine is icariin, and the concentration of the icariin is 40-80 mg/kg. Preferably, the concentration of icariin is 60 mg/kg. Has the advantages that: the icariin is found to have a prevention and treatment effect on irritable bowel syndrome models, and animal experiments prove that the icariin can indeed relieve irritable bowel syndrome induced by comprehensive stimulation. Therefore, the icariin is used for preparing the irritable bowel syndrome medicament, can provide a natural medicament for treating the irritable bowel syndrome, develops a new application field, and provides a basis for the follow-up research of ICA for IBS.
Drawings
FIG. 1 is a graph showing the maximum amount of saline injected in an abdominal withdrawal reflex test.
FIG. 2 is a graph showing the change in the rate of body weight gain of rats.
FIG. 3 is a graph showing the number of fecal pellets in 8h of rats.
Fig. 4 is a graph of stool water content.
FIG. 5 is a pathological picture of colon HE staining; wherein, A-G are HE staining pathological patterns of a blank group (Ctrl group), a Chronic stimulation model group (chrononic group), a Chronic stimulation +3% glacial acetic acid group (compressive group), a low-concentration icariine group (ICA 1 group, 40 mg/kg), a medium-concentration icariine group (ICA 2 group, 60 mg/kg), a high-concentration icariine group (ICA 3 group, 80 mg/kg) and a positive medicine pinaverium bromide group (PB group, 25 mg/kg).
FIG. 6 is a WB result graph; wherein, 1: control group, 2: compressive group, 3: and (5) a medium-concentration ICA2 group (60 mg/kg).
Detailed Description
The invention uses chronic stimulation and chemical stimulation (3% glacial acetic acid enema) as a method for constructing a irritable bowel syndrome model. The experimental period was 21 days, and Wistar rats were randomly divided into 7 groups: blank group (Ctrl group), Chronic stimulation model group (chrononic group), Chronic stimulation +3% glacial acetic acid group (compressive group), low-concentration icariin group (ICA 1 group, 40 mg/kg), medium-concentration icariin group (ICA 2 group, 60 mg/kg), high-concentration icariin group (ICA 3 group, 80 mg/kg), positive drug pinaverium bromide group (PB group, 25 mg/kg), and the number of rats in each group was equal. Icariin is dissolved in anhydrous ethanol, and then dissolved in distilled water, and the final concentration of the anhydrous ethanol is not more than 1/1000. Chronic unpredictable stimuli were administered daily to the model group. Wherein the stimulation comprises water deprivation, fasting, day and night reversal, cold stimulation, wet feeding, pain, braking, and electric shock. The experimental principles comprise: once daily, one stimulus at a time, and the use of the same stimulus prohibited for two consecutive days. The combination factor group was subjected to a 7 day chemically stimulated glacial acetic acid enema on experiment day 8. The experiment adopts a mode of molding and dosing simultaneously, icariin and pinaverium bromide both adopt a comprehensive stimulation model, and the dosing method is gastric lavage dosing, once a day, multiplying the weight of a rat by the corresponding concentration every day and calculating the dose. The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention.
The following examples are given without specific reference, and all technical means used are conventional ones, and all drugs used are commercially available ones.
Experimental animals: male Wistar rats, body weight 180. + -.10 g.
Example 1: visceral hypersensitivity studies described in the present invention.
1. Experimental materials and methods
(1) Experimental materials
The Wistar rat 42 is purchased from Beijing Wintolite laboratory animal technology Limited, the age is 6-8 weeks, the weight of the Wistar rat is about 180g, all rats are placed in an environment with 20-24 ℃ and humidity of 60% -70%, 12 hours of light and 12 hours of dark alternation, the rats can freely eat and water, and the experiment is started after all rats are raised for three days.
(2) Experimental method
Wistar rats were randomly divided into 7 groups: blank group (Ctrl group), Chronic stimulation model group (chrononic group), Chronic stimulation +3% glacial acetic acid group (compressive group), low-concentration icariin group (ICA 1 group, 40 mg/kg), medium-concentration icariin group (ICA 2 group, 60 mg/kg), high-concentration icariin group (ICA 3 group, 80 mg/kg), positive drug pinaverium bromide group (PB group, 25 mg/kg), and the number of rats in each group was equal. Visceral sensitivity was assessed by abdominal withdrawal experiments: the F12 catheter was connected to a 5ml syringe, the balloon coated with the glycerine enema was then inserted about 1.0 cm into the rat anus, and the balloon was secured by tying the plastic catheter to the rat tail root with adhesive tape. The operator injects physiological saline into the bursa randomly and quickly, after reaching the maximum arch back (the maximum arch back state of the rat is that the body is arch-shaped and the pelvis is lifted), the operation is maintained for 20 s, and the air injection is repeated for 3 times at each pressure, and the interval is 4min each time. Observers blindly independently and simultaneously observed abdominal withdrawal reflex of experimental rats and recorded the amount of physiological saline injected.
2. Results of the experiment
The results are shown in fig. 1, with less decrease in abdominal withdrawal reflex threshold in the chronic stimulation group (P < 0.001), and a significant decrease in abdominal withdrawal reflex threshold in the chronic stimulation +3% glacial acetic acid group (P < 0.001), i.e., increased visceral sensitivity. The pain threshold of the chronic stimulation +3% glacial acetic acid group is the lowest, and the pain threshold is increased after icariin or positive drug treatment, wherein the pain threshold of the medium-concentration ICA2 group (60 mg/kg) is obviously increased after icariin treatment (P < 0.001).
Example 2: rat weight gain Rate study described in the present invention
1. Experimental materials and methods
(1) Experimental materials: rats in each experimental group in the visceral hypersensitivity study.
(2) The experimental method comprises the following steps: during the experiment, the rats in each group were weighed on days 0, 7, 14 and 21, respectively.
2. Results of the experiment
As shown in FIG. 2, the weight gain rate was less in the chronic stimulation group (P < 0.001), and significantly decreased in the chronic stimulation +3% glacial acetic acid group (P < 0.001). The weight gain rate of the chronic stimulation and 3% glacial acetic acid group is the lowest, and the weight is increased after the icariin treatment, wherein the weight gain rate of the medium-concentration ICA2 group (60 mg/kg) after the icariin treatment is similar to that of the positive drug group (P < 0.001).
Example 3: stool particle count study described in the present invention
1. Test materials and methods
(1) Experimental materials: rats in each experimental group in the visceral hypersensitivity study.
(2) The experimental method comprises the following steps: each group of rats was placed in a quiet room, one per cage, and the number of defecation pellets in 8 hours was measured for each group of rats.
2. Results of the experiment
The results are shown in fig. 3, and the number of fecal particles in the chronic stimulation group is less increased (P < 0.001), and the number of fecal particles in the chronic stimulation +3% glacial acetic acid group is obviously increased (P < 0.001), i.e. the intestinal sensitivity is increased. The number of the grains of the feces in the chronic stimulation +3% glacial acetic acid group is the largest, and the number of the grains of the feces is reduced after the icariin treatment, wherein the number of the grains of the feces in the middle concentration ICA2 group (60 mg/kg) after the icariin treatment is similar to that in the positive medicine group (P is less than 0.001).
Example 4: study of fecal water content as described in the present invention
1. Experimental materials and methods
(1) Experimental materials: rats in each experimental group were studied for visceral hypersensitivity.
(2) The experimental method comprises the following steps: the rats in each group are placed in a quiet room with one cage, feces are collected and placed in an oven for 4 hours, and the moisture content of the feces of the rats in each group is measured.
2. Results of the experiment
The results are shown in fig. 4, and the water content of feces in the chronic stimulation group is slightly increased (P < 0.001), the water content of feces in the chronic stimulation +3% glacial acetic acid group is obviously increased (P < 0.001), and even watery feces appear. The feces water content of the chronic stimulation +3% glacial acetic acid group is the highest, and the feces water content is reduced after icariin treatment, wherein the feces water content of the medium-concentration ICA2 group (60 mg/kg) is similar to that of the positive drug group (P < 0.001) after icariin treatment.
Example 5: pathological Studies as described in the present invention
1. Experimental materials and methods
(1) Experimental materials: rats in each experimental group in the visceral hypersensitivity study.
(2) The experimental method comprises the following steps: and (5) HE staining.
2. Results
In the research, the colon HE of each group of experimental rats is stained, the result is shown in figure 5, the colon tissues of the rats in the blank group, the model group, each ICA group and the positive medicament pinaverium bromide group are observed, and the local colon tissues of the IBS rat models in each group have no inflammatory cell infiltration, which shows that the IBS has no organic lesion and accords with the IBS clinical diagnosis standard.
Example 6: WB study described in the present invention
1. Test materials and methods
(1) Experimental materials: rats in each experimental group in the visceral hypersensitivity study.
(2) The experimental method comprises the following steps: western Blot.
2. Results
In the study, the 5-HT of colon tissue of rats is tested by Ctrl group, chronic stimulation group +3% glacial acetic acid group, medium-concentration icariin group (ICA 2 group, 60 mg/kg) and pinaverium bromide group 3 A content was measured, and the results are shown in FIG. 6, and the rat 5-HT was treated with chronic stimulation and 3% glacial acetic acid enema 3 The content of A is obviously increased (P)<0.001), while the middle concentration ICA2 group and the positive drug pinaverium bromide group were treated with 5-HT in rats 3 The content of A is obviously reduced (P)<0.001）。
Based on the research results, compared with the control group, the weight growth rate of the rats with the chronic stimulation and 3% glacial acetic acid group is obviously reduced, the pain threshold is the lowest, the stool grain number is obviously increased, and the stool water content is increased. 5-HT 3 A is closely related to the pathogenesis of IBS, and 5-HT is measured by WB 3 A content, found 5-HT 3 The A content is obviously increased, and the intermediate concentration ICA2 group (60 mg/kg) and the positive medicine pinaverium bromide group are 5-HT 3 The content of A is obviously reduced. While the chronic stimulated group had a low rate of weight gain, a low pain threshold, and a low fecal water content. Therefore, chronic stimulation and 3% glacial acetic acid enema are more combined with the characteristic of complex pathogenesis of IBS. After the group with the medium concentration ICA2 is treated by icariin, the weight gain rate, the pain threshold value, the stool grain number and the stool water content are similar to those of the positive medicine group. Therefore, icariin has the effect of treatingHas excellent effect on irritable bowel syndrome at a concentration of 60 mg/kg.
The icariin is found to have a prevention and treatment effect on irritable bowel syndrome models, and animal experiments prove that the icariin can indeed relieve irritable bowel syndrome induced by comprehensive stimulation. Therefore, the icariin is used for preparing the medicine for treating the irritable bowel syndrome, can provide a natural medicine for treating the irritable bowel syndrome, and develops a new application field. Although the mechanism needs to be further researched, the invention provides a basis for the subsequent research of ICA for IBS.
It should be noted that the above-mentioned embodiments illustrate rather than limit the scope of the invention, which is defined by the appended claims. It will be apparent to those skilled in the art that certain insubstantial modifications and adaptations of the present invention can be made without departing from the spirit and scope of the invention.
Claims (5)
1. Application of icariin in preparation of medicine for treating irritable bowel syndrome is provided.
2. Use according to claim 1, characterized in that: the concentration of the icariin is 40-80 mg/kg.
3. Use according to claim 2, characterized in that: the concentration of icariin is 60 mg/kg.
4. A medicament for the treatment of irritable bowel syndrome, characterized by: the active ingredient of the medicine is icariin, and the concentration of the icariin is 40-80 mg/kg.
5. The medicament of claim 4, wherein: the concentration of icariin is 60 mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211005959.5A CN115068494A (en) | 2022-08-22 | 2022-08-22 | Application of icariin in preparation of medicine for treating irritable bowel syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211005959.5A CN115068494A (en) | 2022-08-22 | 2022-08-22 | Application of icariin in preparation of medicine for treating irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115068494A true CN115068494A (en) | 2022-09-20 |
Family
ID=83244390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211005959.5A Pending CN115068494A (en) | 2022-08-22 | 2022-08-22 | Application of icariin in preparation of medicine for treating irritable bowel syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068494A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059520A1 (en) * | 1999-04-01 | 2000-10-12 | Guorang Hu | Herbal compositions and uses for the treatment of allergic reactions |
| US20130123264A1 (en) * | 2011-10-17 | 2013-05-16 | Darren D. Browning | Compositions and methods for treatment of inflammatory bowel disorders and intestinal cancers |
| US20160022681A1 (en) * | 2012-02-14 | 2016-01-28 | University Of Rochester | Methods of increasing lymphatic transport |
| CN106309380A (en) * | 2016-08-19 | 2017-01-11 | 中国医学科学院生物医学工程研究所 | Icariin controlled release microsphere, preparation method thereof and application thereof |
-
2022
- 2022-08-22 CN CN202211005959.5A patent/CN115068494A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059520A1 (en) * | 1999-04-01 | 2000-10-12 | Guorang Hu | Herbal compositions and uses for the treatment of allergic reactions |
| US20130123264A1 (en) * | 2011-10-17 | 2013-05-16 | Darren D. Browning | Compositions and methods for treatment of inflammatory bowel disorders and intestinal cancers |
| US20160022681A1 (en) * | 2012-02-14 | 2016-01-28 | University Of Rochester | Methods of increasing lymphatic transport |
| CN106309380A (en) * | 2016-08-19 | 2017-01-11 | 中国医学科学院生物医学工程研究所 | Icariin controlled release microsphere, preparation method thereof and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| WEN XIONG等: "Icariin enhances intestinal barrier function by inhibiting NF-kB signaling pathways and modulating gut microbiota in a piglet model", 《RSC ADVANCES》 * |
| 丁宁等: "《常见疾病的预防与康复》", 31 July 2020, 东南大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110433289A (en) | For treating the drug of periodontal ligament cell dysfunction and Alveolar Bone Loss caused by Periodontal Pathogens infect | |
| CN115068494A (en) | Application of icariin in preparation of medicine for treating irritable bowel syndrome | |
| CN113509495B (en) | Application of lactobacillus rhamnosus in relieving intestinal inflammation | |
| CN1723936A (en) | Traditional Chinese medicine for treating depressive disorders, and its prepn. method | |
| CN1078081C (en) | Medicine for treating osteoproliferation, rheumatism and rheumatoid arthritis, and preparing method thereof | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN107875144A (en) | A kind of combination of oral medication for treating depression | |
| CN104758348B (en) | A kind of Chinese medicine composition preparation is used for the purposes of tumor chemoradiotherapy related oral ulcer | |
| RU2442224C1 (en) | The method of modeling of the perimaxillary phlegmon | |
| Pillsbury et al. | Relation of Diet to Cutaneous Infection: A Study of the Influence of Varying Carbohydrate and Fat Intakes and of Fasting on Experimental Pyogenic Cutaneous Infections in Dogs, with Comparative Determinations of the Glycogen Content of the Skin and Liver | |
| CN1733290A (en) | Medicine for treating acute and chronic cholecystitis and cholelithiasis, process for preparing the same and application thereof | |
| CN104906132A (en) | Plaster preparation for preventing and treating lamb stomatitis | |
| CN108703963B (en) | Application of anethole in preparing medicine for treating neuropathic pain | |
| CN103933274A (en) | Traditional Chinese medicine preparation for treating periodontitis | |
| CN1240430C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof | |
| CN116392560B (en) | Traditional Chinese medicine composition and medical application thereof | |
| CN115998793B (en) | Vigour-preserving soup for improving learning and memory capacity of organism and preparation method thereof | |
| CN105962184A (en) | Health-care food with function of easing constipation | |
| CN110420209B (en) | Pharmaceutical composition for treating diabetic peripheral neuralgia and application thereof | |
| CN109568397B (en) | Traditional Chinese medicine composition for treating pet ulcerative colitis and preparation method thereof | |
| CN1943701A (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method | |
| CN109045025B (en) | New use of oxidized decursin | |
| CN1270763C (en) | Preparation for removing blood stasis keeping kidney essence | |
| JPH10114652A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same | |
| RU2250774C1 (en) | Method for optimizing chronic prostatitis treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |
|
| RJ01 | Rejection of invention patent application after publication |